Key facts
- Kernalbio’s last known valuation is $110.5M (Jul 2022).
- It has raised $36.1M across 1 recorded rounds; the latest was Later Stage VC (Series A) ($25.0M) in Jul 2022.
- Notable investors include Y Combinator, MassChallenge, Astir Ventures, Gaingels, Calm Ventures — 47 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 47 names
- ·Watchlist + deal alerts for Kernalbio
Funding rounds
1 roundsAbout Kernalbio
Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. The company's platform decreases immunogenicity upon existing mRNA technologies and enables cell-specific therapeutic protein expression, providing clinicians with efficacious, tolerable, and affordable medicine for the global market.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 17
- Website
- kernalbio.com/
- Ownership
- Privately Held (backing)
Kernalbio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kernalbio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kernalbio in its N-PORT filings yet. We sweep new filings monthly.